First AD

Second AD

Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute

, and Associate Professor of Medicine at Harvard Medical School.

Data from the following clinical trial are discussed:

LBA17_PR - Overall survival (OS) results from the phase 3 MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

THE TALK: Breast Cancer

The Talk

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial